The effect of GnRH analog on the results of frozen-thawed embryo transfers.
- Conditions
- InfertilityMedDRA version: 14.1Level: LLTClassification code 10042391Term: SubfertilitySystem Organ Class: 100000004872Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Registration Number
- EUCTR2013-000106-29-FI
- Lead Sponsor
- Turku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
20 - 45 year old women coming to frozen thawed embryo transfer.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 240
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
The age of the woman over 42 year during the initial IVF/ICSI-treatment, from which the embryos derive.
Abnormal uterus
Known abnormality of karyotype of the woman or her partner
Severe male factor as an exclusive reason for subfertillity
Allergy for Gonapeptyl
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To compare the results of frozen.thawed embryo transfers with and without GnRH analog support;Secondary Objective: S-hCG, S-Prog S-E2<br>The lenght of the luteal phase<br>Bleeding in luteal phase;Primary end point(s): Pregnancy rate, implantation rate, miscarriages, live birth rate, multiple birth rate;Timepoint(s) of evaluation of this end point: One year after the last embryo transfer
- Secondary Outcome Measures
Name Time Method Secondary end point(s): S-hCG, S-Prog S-E2<br>The lenght of the luteal phase<br>Bleeding in luteal phase;Timepoint(s) of evaluation of this end point: Within a year from the last embryo transfer